HighTower Advisors
MCRB icon

HighTower Advisors’s Seres Therapeutics MCRB Stock Holding History

HighTower Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,500
Closed -$58.2K – 3922
2024
Q4 		$58.2K Hold
3,500
– – ﹤0.01% 3441
2024
Q3 		$66K Buy
3,500
+750
+27% +$15.2K ﹤0.01% 3375
2024
Q2 		$40K Buy
2,750
+2,000
+267% +$33.4K ﹤0.01% 3329
2024
Q1 		$12K Sell
750
-50
-6% -$1.08K ﹤0.01% 3393
2023
Q4 		$22K Sell
800
-250
-24% -$6.57K ﹤0.01% 3391
2023
Q3 		$50K Hold
1,050
– – ﹤0.01% 3227
2023
Q2 		$101K Buy
1,050
+325
+45% +$35.4K ﹤0.01% 3071
2023
Q1 		$83K Buy
725
+75
+12% +$8.11K ﹤0.01% 2978
2022
Q4 		$73K Hold
650
– – ﹤0.01% 2975
2022
Q3 		$83K Buy
+650
New +$66.6K ﹤0.01% 2803

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighTower Advisors's MCRB Position: Q1 2025 in Review

HighTower Advisors sold out of Seres Therapeutics (MCRB) in Q1 2025, closing a stake of 3,500 shares — an estimated $58.2K sold.

HighTower Advisors first reported a position in MCRB in Q3 2022 and held it in 10 quarters. The position peaked at $101K in Q2 2023. 63 funds tracked by Wall St. Rank hold MCRB as of Q1 2025.

  • HighTower Advisors reported no remaining Seres Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HighTower Advisors sold 3,500 Seres Therapeutics shares in Q1 2025, an estimated $58.2K.
  • HighTower Advisors first reported a position in Seres Therapeutics in Q3 2022 and held it in 10 quarters.
  • HighTower Advisors's Seres Therapeutics position peaked at $101K in Q2 2023.
  • 63 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2025.

Based on HighTower Advisors's 13F filing for Q1 2025, filed 13 May 2025.